Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

530 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-06-30

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

NCT00346866

AMD

COMPLETED PHASE2

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

NCT00299507

Macular Degeneration

COMPLETED PHASE3

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

NCT00051129

Macular Degeneration Maculopathy, Age-Related Age-Related Maculopathies +2 more

COMPLETED PHASE3

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

NCT00211458

Macular Degeneration

COMPLETED PHASE2

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

NCT00346957

AMD

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anecortave and Sham PDT

Group Type ACTIVE_COMPARATOR

Anecortave Acetate 15 mg sterile suspension

Intervention Type DRUG

Photodynamic Therapy (PDT)

Intervention Type OTHER

PDT and Sham Anecortave Acetate

Group Type ACTIVE_COMPARATOR

Anecortave Acetate 15 mg sterile suspension

Intervention Type DRUG

Photodynamic Therapy (PDT)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anecortave Acetate 15 mg sterile suspension

Intervention Type DRUG

Photodynamic Therapy (PDT)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to 20/400 (Snellen equivalent) in the study eye.